{"id":"pna","brandName":"PNA","genericName":"PNA","companyId":"guangzhou-yipinhong-pharmaceutical-co-ltd","companyName":"Guangzhou Yipinhong Pharmaceutical CO.,LTD","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Metacavir Enteric-coated Capsules","Metacavir Enteric-coated Capsules placebo","Metacavir Enteric-coated Capsules Placebo"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"PNA, a drug developed by Guangzhou Yipinhong Pharmaceutical, is currently under investigation for various indications, including acute ischemic stroke and chronic hyponatremia. Despite no FDA approval, it is being studied in multiple clinical trials, with a focus on its efficacy and safety. The drug's mechanism involves modulating inflammatory factors and improving reperfusion outcomes. Key trials include TUKIS and KIF-AIS, both recruiting patients for Phase 2 studies.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PNA is a synthetic peptide that mimics the natural antimicrobial properties of human defensins. It works by binding to bacterial cell membranes and disrupting their integrity, ultimately leading to cell lysis and death.","oneSentence":"PNA is a type of antimicrobial peptide that works by disrupting bacterial cell membranes.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":null,"effect":"N/A"}]},"trials":[],"indications":{"approved":[{"name":"Treatment of various bacterial infections"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}